Sep 08,2022

Ypsomed & Sidekick Health Partner to Improve Therapy Outcomes

Ypsomed and Sidekick Health today announced a collaboration to extend Ypsomed’s device and SmartServices offering by implementing a self-injection module in Sidekick’s proven digital therapeutics solution. The combination of Ypsomed’s devices with Sidekick’s digital health, behavioural economics and gamification expertise will form a unique solution delivering an engaging and personalized patient experience to people with chronic conditions, as well as a turn-key, best-in-class digital therapy management system for pharmaceutical customers. The two companies will jointly develop a set of features and behavioural interventions that support and empower patients throughout the self-injection process and beyond for areas such as oncology, immunology or metabolic diseases.

COLLABORATION PARTNERSHIP

#r&d

#software

View Analyst & Ambassador Comments
Go to original news
Sep 12,2022

Hygieia adds clinical partners in New York and North Carolina to itsd-Nav® Insulin Management Program

Hygieia, a provider of digital therapeutics for insulin management, has added Endocrine Associates of West Village P.C. in Manhattan and Long Island City, NY, and Physicians East in Greenville, NC, as clinical partners. The partnerships are the first in their respective states and make Hygieia’s d-Nav® autonomous insulin therapy service available to more patients with advanced type 2 diabetes.

COLLABORATION PARTNERSHIP

#institution

#software

View Analyst & Ambassador Comments
Go to original news
Oct 13,2022

CCS Announces Innovative Partnership with Welldoc and ZeOmega Aimed at Helping People with Chronic Conditions Lead Healthier Lives while Reducing Healthcare Costs

CCS — leading provider of clinical solutions and home-delivered medical supplies for those living with chronic conditions — has announced a new technology partnership with Welldoc® and ZeOmega to expand its established LivingConnected® solution. The Welldoc digital health tool allows individuals to track device readings and access coaching, and the ZeOmega platform captures utilization patterns and claims data. With the combination of these digital health products powering the LivingConnected® program, certified CCS clinicians will now have real-time visibility into glycemic control to customize member engagement and guide necessary clinical interventions. Also, employers and health plans leveraging LivingConnected® will benefit from being able to better assess the health outcomes and the financial impact of CCS’s holistic chronic care management approach.

COLLABORATION PARTNERSHIP

#product & service

#coaching

#software

View Analyst & Ambassador Comments
Go to original news
Nov 09,2022

MindMaze, Mount Sinai partner on digital neurotherapeutic program

MindMaze, which makes game-like rehabilitation tools for neurological conditions and injuries, announced a partnership with New York-based Mount Sinai Health System to offer a digital therapeutic program for stroke and concussion patients. Under the partnership, Mount Sinai will use MindMaze's software and hardware to provide an outpatient rehab program followed by home-based digital care, assessment and monitoring. The health system and the startup will use data generated from the program to determine its effectiveness and its potential to scale.

COLLABORATION PARTNERSHIP

#r&d

#software

View Analyst & Ambassador Comments
Go to original news
Jul 22,2021

Akili interactive updates video game to give kids more choices while playing

EndeavorRx, the FDA De Novo-authorized video game digital therapeutic for children with ADHD, is getting a slew of new gameplay features, its developer Akili Interactive announced today. EndeavorRx takes the form of a game in which users navigate an alien avatar through a course while they respond to on-screen prompts. The app keeps track of movements, monitors the user’s behavior and quickly adapts to the player.

PRODUCT

#mobile app

#software

View Analyst & Ambassador Comments
Go to original news
Jul 27,2021

Q&A: Head of Happify Health Chris Wasden unpacks how digital therapy makers can tackle consumer and provider adoption barriers

DTx tech is still new in the grand scheme—Happify Health’s head of digital therapeutics walks us through strategies DTx firms can take to overcome some of the biggest barriers to adoption. Chris Wasden, head of digital therapeutics at Happify Health, talks about adoption barriers like the fact that physicians aren’t fully confident prescribing digital therapies, and consumers' privacy concerns amid record-high healthcare data breaches.

PRODUCT

#mobile app

#software

#virtual care

View Analyst & Ambassador Comments
Go to original news
Jul 30,2021

Biofourmis Earns FDA Breakthrough Device Designation for Digital Therapeutic for Heart Failure

Biofourmis, a Boston-based global leader in virtual care and digital therapeutics, announced its BiovitalsHF® solution is the first-ever heart failure digital therapeutic to receive a Breakthrough Device designation from the U.S. Food and Drug Administration (FDA).

REGULATORY FDA

#mobile app

#rpm

#software

View Analyst & Ambassador Comments
Go to original news
Aug 26,2021

Mind Cure Health begins North American release of digital therapeutic for psychedelic therapy

Mind Cure Health, a Canadian startup developing technology platforms to assist mental healthcare and psychedelic research, is releasing a minimum viable product (MVP) version of its flagship digital therapeutic, iSTRYM, in clinics across North America. While the version of iSTRYM initially being released only includes basic features, the digital platform provides data-driven insights to support both patients and providers throughout psychedelic therapy.

PRODUCT

#software

#rpm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Sep 02,2021

Voluntis announces the completion of the acquisition by Aptar of a majority stake in Voluntis at a price of €8.70 per share

Voluntis, a leader in digital therapeutics, and its reference shareholders (Bpifrance Participations, LBO France Gestion, Debiopharm Innovation Fund, SHAM Innovation Santé, Vesalius Biocapital and Indigo) announced today that following the signature of a share purchase agreement with AptarGroup, Inc. (NYSE: ATR) (“Aptar”) on July 22, 2021 and the approval of the French Ministry of Economy under the foreign investment clearance regulations, Aptar has completed the acquisition of a majority stake in Voluntis from the company’s reference shareholders and certain members of the management, representing approximately 64.6% of the share capital of Voluntis (on a non-diluted basis), at a price of €8.70 per share.

COLLABORATION MERGERS & ACQUISITION

#product & service

#mobile app

#software

View Analyst & Ambassador Comments
Go to original news
Mar 29,2021

Full results of EndeavorRx adjunct trial show longer benefits with or without stimulant therapy

Akili Interactive has published the full data from its STARS-ADHD Adjunctive trial. The data builds upon the company's pivotal study of AKL-T01 (now available as EndeavorRx) and suggests the videogame-like digital therapeutic delivers benefits with or without accompanying stimulant medication, and that they persist up to one month following the treatment.

CLINICAL STUDY

#software

View Analyst & Ambassador Comments
Go to original news
Subscribe to SOFTWARE